The Yin-Yang of thrombin and activated protein C

British Journal of Haematology

Volumn 140, Issue 5, 2008, Pages 505-515

  Dutt, Tina ^a   Toh, Cheng Hock ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Activated protein C; Coagulation; Inflammation; PAR 1; Thrombin

Indexed keywords

ACTIVATED PROTEIN C; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOTTING; CHINESE MEDICINE; CLINICAL TRIAL; DRUG MECHANISM; HEMOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOEMBOLISM;

BLOOD COAGULATION; HUMANS; INFLAMMATION; PROTEIN C; SEPSIS; THROMBIN; THROMBOEMBOLISM; YIN-YANG;

EID: 38949115609     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06977.x     Document Type: Review

References (153)

1. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L., Beale, R., Svoboda, P., Laterre, P.F., Simon, S., Light, B., Spapen, H., Stone, J., Seibert, A., Peckelsen, C., De Deyne, C., Postier, R., Pettila, V., Artigas, A., Percell, S.R., Shu, V., Zwingelstein, C., Tobias, J., Poole, L., Stolzenbach, J.C. Creasey, A.A. (2003) Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. The Journal of the American Medical Association, 290, 238 247.
2. Aird, W.C. (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood, 101, 3765 3777.
3. Andersen, H., Greenberg, D.L., Fujikawa, K., Xu, W., Chung, D.W. Davie, E.W. (1999) Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proceedings of the National Academy of Sciences of the United States of America, 96, 11189 11193.
4. Anderson, R.N. Smith, B.L. (2005) Deaths: leading causes for 2002. National Vital Statistics Reports, 53, 1 89.
5. Bae, J.S., Yang, L. Rezaie, A.R. (2007) Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 2867 2872.
6. Bajzar, L., Nesheim, M.E. Tracy, P.B. (1996) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood, 88, 2093 2100.
7. Bar-Shavit, R., Kahn, A.J., Mann, K.G. Wilner, G.D. (1986) Identification of a thrombin sequence with growth factor activity on macrophages. Proceedings of the National Academy of Sciences of the United States of America, 83, 976 980.
8. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W. Fisher, C.J. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine, 344, 699 709.
9. Bertina, R.M., Koeleman, B.P.C., Koster, T., Rosendaal, F.R., Dirven, R.J., de Ronde, H., van der Velden, P.A. Reitsma, P.H. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 64 67.
10. Bevers, E.M., Comfurius, P. Zwaal, R.F.A. (1991) Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Reviews, 5, 146 154.
11. Blombäck, B. (1996) Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thrombosis Research, 83, 1 75.
12. Boskovic, D.S., Giles, A.R. Nesheim, M.E. (1990) Studies of the role of factor Va in the factor Xa-catalyzed activation of prothrombin, fragment 1.2-prethrombin-2, and dansyl-L-glutamyl- glycyl-L-arginine-meizothrombin in the absence of phospholipid. Journal of Biological Chemistry, 265, 10497 10505.
13. Brown, D.A. London, E. (2000) Structure and function of sphingolipid and cholesterol-rich membrane rafts. Journal of Biological Chemistry, 275, 17221 17224.
14. Broze, Jr., G.J. Higuchi, D.A. (1996) Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood, 88, 3815 3823.
15. Buller, H.R., Sohne, M. Middeldorp, S. (2005) Treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis, 3, 1554 1560.
16. Cantwell, A.M. Di Cera, E. (2000) Rational design of a potent anticoagulant thrombin. Journal of Biological Chemistry, 275, 39827 39830.
17. Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen, E.D., Fukudome, K. Zlokovic, B.V. (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nature Medicine, 9, 338 342.
18. Cheng, T., Petraglia, A.L., Li, Z., Thiyagarajan, M., Zhong, Z., Wu, Z., Liu, D., Maggirwar, S.B., Deane, R., Fernandez, J.A., LaRue, B., Griffin, J.H., Chopp, M. Zlokovic, B.V. (2006) Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nature Medicine, 12, 1278 1285.
19. Comp, P.C., Jacocks, R.M., Ferrell, G.L. Esmon, C.T. (1982) Activation of protein C in vivo. Journal of Clinical Investigation, 70, 127 134.
20. Conway, E.M. Rosenberg, R.D. (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Molecular and Cellular Biology, 8, 5588 5592.
21. Coughlin, S.R. (2000) Thrombin signalling and protease-activated receptors. Nature, 407, 258 264.
22. Cutsforth, G.A., Whitaker, R.N., Hermans, J. Lentz, B.R. (1989) A new model to describe extrinsic protein binding to phospholipid membranes of varying composition: application to human coagulation proteins. Biochemistry, 28, 7453 7461.
23. Dahlback, B., Carlsson, M. Svensson, P.J. (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the United States of America, 90, 1004 1008.
24. Davey, M.G. Lüscher, E.F. (1967) Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature, 216, 857 858.
25. Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G., Tuddenham, E.G. McVey, J.H. (2003a) Molecular evolution of the vertebrate blood coagulation network. Thrombosis and Haemostasis, 89, 420 428.
26. Davidson, C.J., Tuddenham, E.G. McVey, J.H. (2003b) 450 million years of hemostasis. Journal of Thrombosis and Haemostasis, 1, 1487 1494.
27. Davie, E.W., Fujikawa, K. Kisiel, W. (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry, 30, 10363 10370.
28. Deguchi, H., Fernandez, J.A., Pabinger, I., Heit, J.A. Griffin, J.H. (2001) Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood, 97, 1907 1914.
29. Deguchi, H., Pecheniuk, N.M., Elias, D.J., Averell, P.M. Griffin, J.H. (2005a) High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation, 112, 893 899.
30. Deguchi, H., Bouma, B.N., Middeldorp, S., Lee, Y.M. Griffin, J.H. (2005b) Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. Journal of Thrombosis and Haemostasis, 3, 935 938.
31. Derechin, V.M., Blinder, M.A. Tollefsen, D.M. (1990) Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition. Journal of Biological Chemistry, 265, 5623 5628.
32. Dhainaut, J.F., Marin, N., Mignon, A. Vinsonneau, C. (2001) Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Critical Care Medicine, 29, S42 47.
33. Dhainaut, J.F., Yan, S.B., Joyce, D.E., Pettila, V., Basson, B., Brandt, J.T., Sundin, D.P. Levi, M. (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2, 1924 1933.
34. Drake, T.A., Cheng, J., Chang, A. Taylor, F.B. (1993) Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. American Journal of Pathology, 142, 1458 1470.
35. Ely, E.W., Laterre, P.F., Angus, D.C., Helterbrand, J.D., Levy, H., Dhainaut, J.F., Vincent, J.L., Macias, W.L. Bernard, G.R. (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Critical Care Medicine, 31, 12 19.
36. Esmon, C.T. (1995) Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. Federation of American Societies for Experimental Biology, 9, 946 955.
37. Esmon, C.T. (2003) The Protein C Pathway. Chest, 124, 26S 32.
38. Esmon, C.T. (2005) The interactions between inflammation and coagulation. British Journal of Haematology, 131, 417 430.
39. Esmon, C.T. Owen, W.G. (1981) Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proceedings of the National Academy of Sciences of the United States of America, 78, 2249 2252.
40. Esmon, C.T., Esmon, N.L. Harris, K.W. (1982) Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. Journal of Biological Chemistry, 257, 7944 7947.
41. Faioni, E.M., Ferrero, S., Fontana, G., Gianelli, U., Ciulla, M.M., Vecchi, M., Saibeni, S., Biguzzi, E., Cordani, N., Franchi, F., Bosari, S. Cattaneo, M. (2004) Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Critical Care Medicine, 32, S266 S270.
42. Faust, S.N., Levin, M., Harrison, O.B., Goldin, R.D., Lockhart, M.S., Kondaveeti, S., Laszik, Z., Esmon, C.T. Heyderman, R.S. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. New England Journal of Medicine, 345, 408 416.
43. Feinman, R.D., Yuan, A.I., Windwer, S.R. Wang, D. (1985) Kinetics of the reaction of thrombin and alpha 2-macroglobulin. Journal of Biochemistry, 231, 417 423.
44. Feistritzer, C. Riewald, M. (2005) Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood, 105, 3178 3184.
45. Feistritzer, C., Sturn, D.H., Kaneider, N.C., Djanani, A. Wiedermann, C.J. (2003) Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. Journal of Allergy and Clinical Immunology, 112, 375 381.
46. Feistritzer, C., Mosheimer, B.A., Sturn, D.H., Riewald, M., Patsch, J.R. Wiedermann, C.J. (2006) Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. The Journal of Immunology, 176, 1019 1025.
47. Fernandez, J.A., Kojima, K., Petaja, J., Hackeng, T.M. Griffin, J.H. (2000) Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cells, Molecules & Diseases, 26, 115 123.
48. Fernlund, P. Stenflo, J. (1982) Amino acid sequence of the light chain of bovine protein C. Journal of Biological Chemistry, 257, 12170 12179.
49. Finigan, J.H., Dudek, S.M., Singleton, P.A., Chiang, E.T., Jacobson, J.R., Camp, S.M., Ye, S.Q. Garcia, J.G.N. (2005) Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. Journal of Biological Chemistry, 280, 17286 17293.
50. Fletcher, J.R., McKee, A.E., Mills, M., Snyder, K.C. Herman, C.M. (1976) Twenty-four hour membrane oxygenation in dogs without anticoagulation. Surgery, 80, 214 223.
51. de Fouw, N.J., van Hinsbergh, V.W., de Jong, Y.F., Haverkate, F. Bertina, R.M. (1987) The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thrombosis and Haemostasis, 57, 176 182.
52. Frenette, P.S., Mayadas, T.N., Rayburn, H., Hynes, R.O. Wagner, D.D. (1996) Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell, 84, 563 574.
53. Fukudome, K. Esmon, C.T. (1995) Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). Journal of Biological Chemistry, 270, 5571 5577.
54. Fukudome, K., Kurosawa, S., Stearns-Kurosawa, D.J., He, X., Rezaie, A.R. Esmon, C.T. (1996) The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. Journal of Biological Chemistry, 271, 17491 17498.
55. Fukudome, K., Ye, X., Tsuneyoshi, N., Tokunaga, O., Sugawara, K., Mizokami, H. Kimoto, M. (1998) Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. The Journal of Experimental Medicine, 187, 1029 1035.
56. Galligan, L., Livingstone, W., Volkov, Y., Hokamp, K., Murphy, C., Lawler, M., Fukudome, K. Smith, O. (2001) Characterization of protein C receptor expression in monocytes. British Journal of Haematology, 115, 408 414.
57. Goldsack, N.R., Chambers, R.C., Dabbagh, K. Laurent, G.J. (1998) Molecules in focus thrombin. The International Journal of Biochemistry & Cell Biology, 30, 641 646.
58. Govers-Riemslag, J.W., Janssen, M.P., Zwaal, R.F. Rosing, J. (1994) Prothrombin activation on dioleoylphosphatidylcholine membranes. European Journal of Biochemistry, 220, 131 138.
59. Grey, S.T. Hancock, W.W. (1996) A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. Journal of Immunology, 156, 2256 2263.
60. Griffin, J.H., Kojima, K., Banka, C.L., Curtiss, L.K. Fernandez, J.A. (1999) High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. The Journal of Clinical Investigation, 103, 219 227.
61. Griffin, J.H., Fernández, J.A. Deguchi, H. (2001) Plasma lipoproteins, hemostasis and thrombosis. Thrombosis and Haemostasis, 86, 386 394.
62. Gruber, A. Griffin, J.H. (1992) Direct detection of activated protein C in blood from human subjects. Blood, 79, 2340 2348.
63. Gruber, A., Marzec, U.M., Bush, L., Di Cera, E., Fernandez, J.A., Berny, M.A., Tucker, E.I., McCarty, O.J.T., Griffin, J.H. Hanson, S.R. (2007) Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood, 109, 3733 3740.
64. Gu, M.D. (2003) The Taiji diagram: a meta-sign in Chinese thought. Journal of Chinese Philosophy, 30, 195 218.
65. Gu, J.-M., Katsuura, Y., Ferrell, G.L., Grammas, P. Esmon, C.T. (2000) Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood, 95, 1687 1693.
66. Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J.A., Griffin, J.H. Zlokovic, B.V. (2004) Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron, 41, 563 572.
67. Hamberg, M., Svensson, J. Samuelsson, B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America, 72, 2994 2998.
68. Hamilton, J.R., Moffatt, J.D., Frauman, A.G. Cocks, T.M. (2001) Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. Journal of Cardiovascular Pharmacology, 38, 108 119.
69. Heeb, M.J. Griffin, J.H. (1988) Physiologic inhibition of human activated protein C by alpha 1- antitrypsin. Journal of Biological Chemistry, 263, 11613 11616.
70. Hoogendoorn, H., Toh, C.H., Nesheim, M.E. Giles, A.R. (1991) Alpha 2-macroglobulin binds and inhibits activated protein C. Blood, 78, 2283 2290.
71. Hurtado, V., Montes, R., Gris, J.-C., Bertolaccini, M.L., Alonso, A., Martinez-Gonzalez, M.A., Khamashta, M.A., Fukudome, K., Lane, D.A. Hermida, J. (2004) Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood, 104, 1369 1374.
72. Ishihara, H., Connolly, A.J., Zeng, D., Kahn, M.L., Wu Zheng, Y., Timmons, C., Tram, T. Coughlin, S.R. (1997) Protease-activated receptor 3 is a second thrombin receptor in humans. Nature, 386, 502 506.
73. Iwaki, T., Cruz, D.T., Martin, J.A. Castellino, F.J. (2005) A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse. Blood, 105, 2364 2371.
74. Jesty, J. (1986) The kinetics of inhibition of alpha-thrombin in human plasma. Journal of Biological Chemistry, 261, 10313 10318.
75. Joyce, D.E., Gelbert, L., Ciaccia, A., DeHoff, B. Grinnell, B.W. (2001) Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. Journal of Biological Chemistry, 276, 11199 11203.
76. Kadir, A.R., Economides, D.L., Sabin, C.A., Owens, D. Lee, C.A. (1999) Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Journal of Thrombosis and Haemostasis, 82, 1456 1461.
77. Kerlin, B.A., Yan, S.B., Isermann, B.H., Brandt, J.T., Sood, R., Basson, B.R., Joyce, D.E., Weiler, H. Dhainaut, J.-F. (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood, 102, 3085 3092.
78. Kisiel, W., Canfield, W.M., Ericsson, L.H. Davie, E.W. (1977) Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry, 16, 5824 5831.
79. Kurosawa, S., Esmon, C.T. Stearns-Kurosawa, D.J. (2000) The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. The Journal of Immunology, 165, 4697 4703.
80. Laszik, Z., Mitro, A., Taylor, Jr., F.B., Ferrell, G. Esmon, C.T. (1997) Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation, 96, 3633 3640.
81. Lee, R. (2001) Factor V Leiden: a clinical review. The American Journal of the Medical Sciences, 322, 88 102.
82. Lentz, B.R. (2003) Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Progress in Lipid Research, 42, 423 438.
83. Lentz, S.R., Tsiang, M. Sadler, J.E. (1991) Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood, 77, 542 550.
84. Li, W., Zheng, X., Gu, J., Hunter, J., Ferrell, G.L., Lupu, F., Esmon, N.L. Esmon, C.T. (2005) Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. Journal of Thrombosis and Haemostasis, 3, 1351 1359.
85. Liu, D., Cheng, T., Guo, H., Fernandez, J.A., Griffin, J.H., Song, X. Zlokovic, B.V. (2004) Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nature Medicine, 10, 1379 1383.
86. Ludeman, M.J., Kataoka, H., Srinivasan, Y., Esmon, N.L., Esmon, C.T. Coughlin, S.R. (2005) PAR1 cleavage and signaling in response to activated protein C and thrombin. Journal of Biological Chemistry, 280, 13122 13128.
87. Mann, K.G., Brummel, K. Butenas, S. (2003) What is all that thrombin for? Journal of Thrombosis and Haemostasis, 1, 1504 1514.
88. Marciniak, E., Wilson, H.D. Marlar, R.A. (1985) Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood, 65, 15 20.
89. Marlar, R.A. Neumann, A. (1990) Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Seminars in Thrombosis and Hemostasis, 16, 299 309.
90. Marlar, R.A., Kleiss, A.J. Griffin, J.H. (1982) Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood, 59, 1067 1072.
91. Maruyama, I., Salem, H.H., Ishii, H. Majerus, P.W. (1985) Human thrombomodulin is not an efficient inhibitor of the procoagulant activity of thrombin. Journal of Clinical Investigation, 75, 987 991.
92. Medina, P., Navarro, S., Estellés, A., Vayá, A., Woodhams, B., Mira, Y., Villa, P., Migaud-Fressart, M., Ferrando, F., Aznar, J., Bertina, R.M. España, F. (2004) Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Journal of Thrombosis and Haemostasis, 91, 905 911.
93. Minami, T., Sugiyama, A., Wu, S.Q., Abid, R., Kodama, T. Aird, W.C. (2004) Thrombin and phenotypic modulation of the endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 41 53.
94. de Moerloose, P. Boehlen, F. (2007) Inherited thrombophilia in arterial disease: a selective review. Seminars in Hematology, 44, 106 113.
95. Montes, R., Hurtado, V., Alonso, A., Foco, L., Zonzin, P., Mannucci, P.M. Hermida, J. (2005) Autoantibodies against the endothelial receptor of protein C are associated with acute myocardial infarction in young women. Journal of Thrombosis and Haemostasis, 3, 1454 1458.
96. Moore, K.L., Andreoli, S.P., Esmon, N.L., Esmon, C.T. Bang, N.U. (1987) Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. Journal of Clinical Investigation, 79, 124 130.
97. Mosnier, L.O., Zlokovic, B.V. Griffin, J.H. (2007) The cytoprotective protein C pathway. Blood, 109, 3161 3172.
98. Moyer, M.P., Tracy, R.P., Tracy, P.B., Veer, C.V., Sparks, C.E. Mann, K.G. (1998) Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 458 465.
99. Nick, J.A., Coldren, C.D., Geraci, M.W., Poch, K.R., Fouty, B.W., O'Brien, J., Gruber, M., Zarini, S., Murphy, R.C., Kuhn, K., Richter, D., Kast, K.R. Abraham, E. (2004) Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood, 104, 3878 3885.
100. van Nieuw Amerongen, G.P., Draijer, R., Vermeer, M.A. van Hinsbergh, V.W.M. (1998) Transient and prolonged increase in endothelial permeability induced by histamine and thrombin: role of protein kinases, calcium, and RhoA. Circulation Research, 83, 1115 1123.
101. Oganesyan, V., Oganesyan, N., Terzyan, S., Qu, D., Dauter, Z., Esmon, N.L. Esmon, C.T. (2002) The crystal structure of the endothelial protein C receptor and a bound phospholipid. Journal of Biological Chemistry, 277, 24851 24854.
102. Oka, S., Gabazza, E.C., Taguchi, Y., Yamaguchi, M., Nakashima, S., Suzuki, K., Adachi, Y. Imoto, I. (2000) Role of activated protein C in helicobacter pylori-associated gastritis. Infection and Immunity, 68, 2863 2869.
103. Okajima, K., Koga, S., Kaji, M., Inoue, M., Nakagaki, T., Funatsu, A., Okabe, H., Takatsuki, K. Aoki, N. (1990) Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Journal of Thrombosis and Haemostasis, 63, 48 53.
104. Osterud, B. Rapaport, S.I. (1977) Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proceedings of the National Academy of Sciences of the United States of America, 74, 5260 5264.
105. Palareti, G., Legnani, C., Cosmi, B., Valdre, L., Lunghi, B., Bernardi, F. Coccheri, S. (2003) Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation, 108, 313 318.
106. Perez-Casal, M., Downey, C., Fukudome, K., Marx, G. Toh, C.H. (2005) Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood, 105, 1515 1522.
107. Powell, M.G., Hedlin, A.M., Cerskus, I., Kakis, G., Prudham, D. Rosenrot, P. (1984) Effects of oral contraceptives on lipoprotein lipids: a prospective study. Obstetrics & Gynecology, 63, 764 770.
108. Price, D.T. Ridker, P.M. (1997) Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Annals of Internal Medicine, 127, 895 903.
109. Prigozy, T.I., Naidenko, O., Qasba, P., Elewaut, D., Brossay, L., Khurana, A., Natori, T., Koezuka, Y., Kulkarni, A. Kronenberg, M. (2001) Glycolipid antigen processing for presentation by CD1d molecules. Science, 291, 664 667.
110. Qu, D., Wang, Y., Esmon, N.L. Esmon, C.T. (2007) Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. Journal of Thrombosis and Haemostasis, 5, 395 402.
111. Regan, L.M., Stearns-Kurosawa, D.J., Kurosawa, S., Mollica, J., Fukudome, K. Esmon, C.T. (1996) The endothelial cell protein C receptor inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. Journal of Biological Chemistry, 271, 17499 17503.
112. Rezaie, A.R. (2001) Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Journal of Biological Chemistry, 276, 15567 15570.
113. Ridker, P. (2004) Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. The American Heart Hospital Journal, 2, 4 9.
114. Riewald, M. Ruf, W. (2005) Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. Journal of Biological Chemistry, 280, 19808 19814.
115. Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M. Ruf, W. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 296, 1880 1882.
116. Rosenberg, R.D. Rosenberg, J.S. (1984) Natural anticoagulant mechanisms. Journal of Clinical Investigation, 74, 1 6.
117. Rosing, J., Middeldorp, S., Curvers, J., Thomassen, M.C.L.G., Nicolaes, G.A.F., Meijers, J.C.M., Bouma, B.N., Buller, H.R., Prins, M.H. Tans, G. (1999) Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. The Lancet, 354, 2036 2040.
118. Rota, S., McWilliam, N.A., Baglin, T.P. Byrne, C.D. (1998) Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood, 91, 508 515.
119. Ruf, W. (2005) Is APC activation of endothelial cell PAR1 important in severe sepsis?: Yes. Journal of Thrombosis and Haemostasis, 3, 1912 1914.
120. Sakata, Y. Aoki, N. (1982) Significance of cross-linking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. Journal of Clinical Investigation, 69, 536 542.
121. Sapet, C., Simoncini, S., Loriod, B., Puthier, D., Sampol, J., Nguyen, C., Dignat-George, F. Anfosso, F. (2006) Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood, 108, 1868 1876.
122. Saposnik, B., Reny, J.-L., Gaussem, P., Emmerich, J., Aiach, M. Gandrille, S. (2004) A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood, 103, 1311 1318.
123. Scaldaferri, F., Sans, M., Vetrano, S., Graziani, C., De Cristofaro, R., Gerlitz, B., Repici, A., Arena, V., Malesci, A., Panes, J., Grinnell, B.W. Danese, S. (2007) Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. The Journal of Clinical Investigation, 117, 1951 1960.
124. Schutgens, R.E.G., Ackermark, P., Haas, F.J.L.M., Nieuwenhuis, H.K., Peltenburg, H.G., Pijlman, A.H., Pruijm, M., Oltmans, R., Kelder, J.C. Biesma, D.H. (2003) Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. Circulation, 107, 593 597.
125. Scully, M.F., Toh, C.H., Hoogendoorn, H., Manuel, R.P., Nesheim, M.E., Solymoss, S. Giles, A.R. (1993) Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 69, 448 453.
126. Shen, L. Lorand, L. (1983) Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. Journal of Clinical Investigation, 71, 1336 1341.
127. Shibata, M., Kumar, S.R., Amar, A., Fernandez, J.A., Hofman, F., Griffin, J.H. Zlokovic, B.V. (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation, 103, 1799 1805.
128. Shorr, A., Bernard, G., Dhainaut, J.-F., Russell, J., Macias, W., Nelson, D. Sundin, D. (2006) Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Critical Care, 10, R92.
129. Simons, K. Ikonen, E. (1997) Functional rafts in cell membranes. Nature, 387, 569 572.
130. Smirnov, M.D. Esmon, C.T. (1994) Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. Journal of Biological Chemistry, 269, 816 819.
131. Stearns-Kurosawa, D.J., Kurosawa, S., Mollica, J.S., Ferrell, G.L. Esmon, C.T. (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proceedings of the National Academy of Sciences of the United States of America, 93, 10212 10216.
132. Stearns-Kurosawa, D.J., Swindle, K., D'Angelo, A., Della Valle, P., Fattorini, A., Caron, N., Grimaux, M., Woodhams, B. Kurosawa, S. (2002) Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood, 99, 526 530.
133. Sturn, D.H., Kaneider, N.C., Feistritzer, C., Djanani, A., Fukudome, K. Wiedermann, C.J. (2003) Expression and function of the endothelial protein C receptor in human neutrophils. Blood, 102, 1499 1505.
134. Suzuki, K., Deyashiki, Y., Nishioka, J., Kurachi, K., Akira, M., Yamamoto, S. Hashimoto, S. (1987) Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. Journal of Biological Chemistry, 262, 611 616.
135. Takano, S., Kimura, S., Ohdama, S. Aoki, N. (1990) Plasma thrombomodulin in health and diseases. Blood, 76, 2024 2029.
136. Taylor, F.B. Kinasewitz, G. (2004) Activated protein C in sepsis. Journal of Thrombosis and Haemostasis, 2, 708 717.
137. Taylor, F.B.J., Chang, A., Esmon, C.T., D'Angelo, A., Vigano-D'Angelo, S. Blick, K.E. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. The Journal of Clinical Investigation, 79, 918 925.
138. Taylor, F.B.J., Stearns-Kurosawa, D.J., Kurosawa, S., Ferrell, G., Chang, A.C.K., Laszik, Z., Kosanke, S., Peer, G. Esmon, C.T. (2000) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood, 95, 1680 1686.
139. Taylor, F.B.J., Peer, G.T., Lockhart, M.S., Ferrell, G. Esmon, C.T. (2001) Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood, 97, 1685 1688.
140. Tesfamariam, B., Allen, G.T., Normandin, D. Antonaccio, M.J. (1993) Involvement of the "tethered ligand" receptor in thrombin-induced endothelium-mediated relaxations. American Journal of Physiology, 265, H1744 1749.
141. Toh, C.H. (1997) Anticoagulants for venous thrombosis. Postgraduate Medical Journal, 73, 283 285.
142. Vehar, G.A. Davie, E.W. (1980) Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry, 19, 401 410.
143. Vincent, J.L., Bernard, G.R., Beale, R., Doig, C., Putensen, C., Dhainaut, J.F., Artigas, A., Fumagalli, R., Macias, W., Wright, T., Wong, K., Sundin, D.P., Turlo, M.A. Janes, J. (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Critical Care Medicine, 33, 2266 2277.
144. de Visser, M.C.H., Rosendaal, F.R. Bertina, R.M. (1999) A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood, 93, 1271 1276.
145. Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Penzes, I., Kubler, A., Knaub, S., Keinecke, H.-O., Heinrichs, H., Schindel, F., Juers, M., Bone, R.C. Opal, S.M. (2001) High-dose antithrombin III in severe sepsis: a randomized controlled trial. The Journal of the American Medical Association, 286, 1869 1878.
146. Waselenko, J.K., Nace, M.C. Alving, B. (1998) Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Seminars in Thrombosis and Hemostasis, 24, 33 39.
147. Wu, S.-Q. Aird, W.C. (2005) Thrombin, TNF-{alpha}, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells. The American Journal of Physiology. Heart and Circulatory Physiology, 289, H873 885.
148. Xu, J., Qu, D., Esmon, N.L. Esmon, C.T. (2000) Metalloproteolytic release of endothelial cell protein C receptor. Journal of Biological Chemistry, 275, 6038 6044.
149. Xue, M., Campbell, D., Sambrook, P.N., Fukudome, K. Jackson, C.J. (2005) Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. Journal of Investigative Dermatology, 125, 1279 1285.
150. Xue, M., March, L., Sambrook, P.N., Fukudome, K. Jackson, C.J. (2007) Endothelial protein C receptor is over-expressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes. Annals of the Rheumatic Diseases, 66, 1574 1580.
151. Yan, S.B., Helterbrand, J.D., Hartman, D.L., Wright, T.J. Bernard, G.R. (2001) Low levels of protein C are associated with poor outcome in severe sepsis. Chest, 120, 915 922.
152. Yegneswaran, S., Deguchi, H. Griffin, J.H. (2003) Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human and bovine activated protein C with negatively charged phospholipid vesicles. Journal of Biological Chemistry, 278, 14614 14621.
153. Yin, Y.-J., Salah, Z., Grisaru-Granovsky, S., Cohen, I., Even-Ram, S.C., Maoz, M., Uziely, B., Peretz, T. Bar-Shavit, R. (2003) Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 940 944.